Epigallocatechin-3-gallate attenuates transforming growth factor-β1 induced epithelial-mesenchymal transition via Nrf2 regulation in renal tubular epithelial cells

Biomedicine and Pharmacotherapy

Volumn 70, Issue C, 2015, Pages 260-267

  Wang, Yanqiu ^a   Liu, Na ^b   Su, Xuesong ^a   Zhou, Guangyu ^a   Sun, Guangping ^a   Du, Feng ^a   Bian, Xiaohui ^a   Wang, Bowen ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Ordos Central Hospital   (China)

Author keywords

EGCG; EMT; Nrf2; NRK 52E; TGF 1 Smad

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; EPIGALLOCATECHIN GALLATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; CATECHIN; NFE2L2 PROTEIN, RAT;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; IMMUNOFLUORESCENCE; IN VITRO STUDY; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; EPITHELIUM CELL; KIDNEY PROXIMAL TUBULE; PHYSIOLOGY;

ANIMALS; CATECHIN; CELL LINE; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; KIDNEY TUBULES, PROXIMAL; NF-E2-RELATED FACTOR 2; RATS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84927509957     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.01.032     Document Type: Article

References (45)

1. Chatziantoniou C., Dussaule J.C. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?. Am J Physiol Renal Physiol 2005, 289:F227-F234.
2. Lan H.Y. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003, 12:25-29.
3. Lan H.Y. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 2011, 7:1056-1067.
4. Bottinger E.P. TGF-beta in renal injury and disease. Semin Nephrol 2007, 27:309-320.
5. Zhao T.T., Zhang H.J., Lu X.G., Huang X.R., Zhang W.K., Wang H., et al. Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-beta/Smad3 signaling. PLOS ONE 2014, 9:e90807.
6. Ryoo I.G., Shin D.H., Kang K.S., Kwak M.K. Involvement of Nrf2-GSH signaling in TGFbeta1-stimulated epithelial-to-mesenchymal transition changes in rat renal tubular cells. Arch Pharmacal Res 2014, 9(4):e93265.
7. Kim D., Lee A.S., Jung Y.J., Yang K.H., Lee S., Park S.K., et al. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor alpha-mediated transforming growth factor-beta1/Smad signaling pathway Nephrology, dialysis, transplantation. Off Publ Eur Dial Transpl Assoc: Eur Renal Assoc 2014.
8. Liu G.X., Li Y.Q., Huang X.R., Wei L.H., Zhang Y., Feng M., et al. Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension. Clin Sci 2014, 127:195-208.
9. Flanders K.C., Sullivan C.D., Fujii M., Sowers A., Anzano M.A., Arabshahi A., et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002, 160:1057-1068.
10. Bonniaud P., Kolb M., Galt T., Robertson J., Robbins C., Stampfli M., et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol 2004, 173:2099-2108.
11. Fujimoto M., Maezawa Y., Yokote K., Joh K., Kobayashi K., Kawamura H., et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003, 305:1002-1007.
12. Isono M., Chen S., Hong S.W., Iglesias-de la Cruz M.C., Ziyadeh F.N. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002, 296:1356-1365.
13. Meng X.M., Huang X.R., Chung A.C., Qin W., Shao X., Igarashi P., et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol: JASN 2010, 21:1477-1487.
14. Lan H.Y., Chung A.C. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012, 32:236-243.
15. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006, 69:213-217.
16. Gagliardini E., Benigni A. Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytok Growth Factor Rev 2006, 17:89-96.
17. Himmelfarb J., Hakim R.M. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003, 12:593-598.
18. Vaziri N.D. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004, 13:93-99.
19. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004, 24:469-473.
20. Hochmuth C.E., Biteau B., Bohmann D., Jasper H. Redox regulation by Keap1 and Nrf2 controls intestinal stem cell proliferation in Drosophila. Cell Stem Cell 2011, 8:188-199.
21. Villeneuve N.F., Lau A., Zhang D.D. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal 2010, 13:1699-1712.
22. Kobayashi M., Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005, 7:385-394.
23. Wakabayashi N., Slocum S.L., Skoko J.J., Shin S., Kensler T.W. When NRF2 talks, who's listening?. Antioxid Redox Signal 2010, 13:1649-1663.
24. Aminzadeh M.A., Nicholas S.B., Norris K.C., Vaziri N.D. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transpl: Off Publ Eur Dial Transpl Assoc: Eur Renal Assoc 2013, 28:2038-2045.
25. Aleksunes L.M., Goedken M.J., Rockwell C.E., Thomale J., Manautou J.E., Klaassen C.D. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 2010, 335:2-12.
26. Tsai P.Y., Ka S.M., Chao T.K., Chang J.M., Lin S.H., Li C.Y., et al. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radic Biol Med 2011, 50:1503-1516.
27. Oh C.J., Kim J.Y., Min A.K., Park K.G., Harris R.A., Kim H.J., et al. Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling. Free Radic Biol Med 2012, 52:671-682.
28. Suganuma M., Okabe S., Sueoka N., Sueoka E., Matsuyama S., Imai K., et al. Green tea and cancer chemoprevention. Mutat Res 1999, 428:339-344.
29. Peng A., Ye T., Rakheja D., Tu Y., Wang T., Du Y., et al. The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int 2011, 80:601-611.
30. Kakuta Y., Okumi M., Isaka Y., Tsutahara K., Abe T., Yazawa K., et al. Epigallocatechin-3-gallate protects kidneys from ischemia reperfusion injury by HO-1 upregulation and inhibition of macrophage infiltration. Transpl Int: Off J Eur Soc Organ Transpl 2011, 24:514-522.
31. Yamabe N., Yokozawa T., Oya T., Kim M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006, 319:228-236.
32. Nakagawa T., Yokozawa T., Sano M., Takeuchi S., Kim M., Minamoto S. Activity of (-)-epigallocatechin 3-O-gallate against oxidative stress in rats with adenine-induced renal failure. J Agric Food Chem 2004, 52:2103-2107.
33. Chang E.J., Mun K.C. Effect of epigallocatechin gallate on renal function in cyclosporine-induced nephrotoxicity. Transplant Proc 2004, 36:2133-2134.
34. Hisamura F., Kojima-Yuasa A., Kennedy D.O., Matsui-Yuasa I. Protective effect of green tea extract and tea polyphenols against FK506-induced cytotoxicity in renal cells. Basic Clin Pharmacol Toxicol 2006, 98:192-196.
35. Zhou P., Yu J.F., Zhao C.G., Sui F.X., Teng X., Wu Y.B. Therapeutic potential of EGCG on acute renal damage in a rat model of obstructive nephropathy. Mol Med Rep 2013, 7:1096-1102.
36. Zavadil J., Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774.
37. Cui Y., Robertson J., Maharaj S., Waldhauser L., Niu J., Wang J., et al. Oxidative stress contributes to the induction and persistence of TGF-beta1 induced pulmonary fibrosis. Int J Biochem Cell Biol 2011, 43:1122-1133.
38. Barnes J.L., Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int 2011, 79:944-956.
39. Xiao J., Ho C.T., Liong E.C., Nanji A.A., Leung T.M., Lau T.Y., et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr 2014, 53:187-199.
40. Dickinson D., DeRossi S., Yu H., Thomas C., Kragor C., Paquin B., et al. Epigallocatechin-3-gallate modulates anti-oxidant defense enzyme expression in murine submandibular and pancreatic exocrine gland cells and human HSG cells. Autoimmunity 2014, 47:177-184.
41. Chen W.C., Hsieh S.R., Chiu C.H., Hsu B.D., Liou Y.M. Molecular identification for epigallocatechin-3-gallate-mediated antioxidant intervention on the H2O2-induced oxidative stress in H9c2 rat cardiomyoblasts. J Biomed Sci 2014, 21:56.
42. Cho H.J., Kang J.H., Kim T., Park K.K., Kim C.H., Lee I.S., et al. Suppression of PAI-1 expression through inhibition of the EGFR-mediated signaling cascade in rat kidney fibroblast by ascofuranone. J Cell Biochem 2009, 107:335-344.
43. Jiang Z., Seo J.Y., Ha H., Lee E.A., Kim Y.S., Han D.C., et al. Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 2003, 309:961-966.
44. Iglesias-De La Cruz M.C., Ruiz-Torres P., Alcami J., Diez-Marques L., Ortega-Velazquez R., Chen S., et al. Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int 2001, 59:87-95.
45. Chang J.Z., Yang W.H., Deng Y.T., Chen H.M., Kuo M.Y. EGCG blocks TGFbeta1-induced CCN2 by suppressing JNK and p38 in buccal fibroblasts. Clin Oral Investig 2013, 17:455-461.